The European Medicines Agency (EMA) has given its approval to Bio-Thera Solutions for BAT1706 (Avzivi®, bevacizumab), a biosimilar of Avastin®.

Suflave was approved by the FDA on June 15, 2023. It is a prescription laxative used to cleanse the bowel in preparation for colonoscopy in adults.

Connext has revealed the initial successful administration of CNT201, its therapeutic solution for Dupuytren’s contracture, in patients.

Aug 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vertex reveals FDA approval of New Drug Application for Suzetrigine for treating moderate-to-severe acute pain.

The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.

PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.

durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.

Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.

Yes, epcoritamab, marketed under the brand name Epkinly, is FDA approved. It received approval on May 19, 2023.

Celldex Therapeutics announces successful findings from Phase 2 trial of Barzolvolimab for chronic inducible urticaria.

Beremagene geperpavec topical, marketed under the brand name Vyjuvek, is an FDA-approved medication for treating wounds caused by dystrophic epidermolysis bullosa (DEB).